Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.

@article{FengerEriksen2008FibrinogenCS,
  title={Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.},
  author={Christian Fenger-Eriksen and Martin Lindberg-Larsen and Abeline Christensen and J{\o}rgen Ingerslev and Benny S{\o}rensen},
  journal={British journal of anaesthesia},
  year={2008},
  volume={101 6},
  pages={
          769-73
        }
}
BACKGROUND Patients experiencing massive haemorrhage are at high risk of developing coagulopathy through loss, consumption, and dilution of coagulation factors and platelets. It has been reported that plasma fibrinogen concentrations may reach a critical low level relatively early during bleeding, calling for replacement fibrinogen therapy. Cryoprecipitate has been widely used in the past, but more recently, a pasteurized fibrinogen concentrate has become available. We audited the effects of… 
View on PubMed
bjanaesthesia.org
263 Citations
Highly Influential Citations
5
Background Citations
52
Methods Citations
6
Results Citations
5

263 Citations

Citation Type

Citation Type

Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery
TLDR
Fibr inogen concentrate was effective in increasing plasma fibrinogen level, and contributed to the correction of bleeding after cardiovascular surgery.
Fibrinogen replacement therapy: a critical review of the literature.
TLDR
As FFP has several limitations including a low fibrinogen content, which means that large volumes must be given, and the risk of transfusion-related complications, this critical analysis is focused on the role of cryoprecipitate and fibr inogen concentrate.
Fibrinogen concentrate as first-line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100×10(9)/L.
TLDR
FIBTEM-guided administration of fibrinogen concentrate reduced transfusion requirements when used as a first-line haemostatic therapy during aortic surgery in patients with platelet counts over or under 100×10(9)/L.
Effect of volume replacement therapy on coagulation : dilutional coagulopathy
TLDR
Fibrinogen levels decrease at an early stage in severe haemorrhage, and priority must be given to early and effective correction of impaired fibrin polymerization by administering fibr inogen concentrate in multiple trauma patients.
Fibrinolysis , and Platelet Function Prophylactic Fibrinogen Infusion in Cardiac Surgery Patients : Effects on Biomarkers of Coagulation ,
TLDR
Infusion of 2 g fibrinogen to cardiac surgery patients, without hereditary or acquired fibr inogen deficiency or ongoing bleeding, results in no or minimal changes in biomarkers reflecting coagulation and platelet function.
Prophylactic Fibrinogen Infusion in Cardiac Surgery Patients: Effects on Biomarkers of Coagulation, Fibrinolysis, and Platelet Function
TLDR
Infusion of 2 g fibrinogen to cardiac surgery patients, without hereditary or acquired fibr inogen deficiency or ongoing bleeding, results in no or minimal changes in biomarkers reflecting coagulation and platelet function.
Severe bleeding in surgical and trauma patients: the role of fibrinogen replacement therapy.
  • D. Spahn
  • Medicine
    Thrombosis research
  • 2012
Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register
  • G. Weiss, S. Lison, +6 authors B. Heindl
  • Medicine, Biology
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • 2011
TLDR
Clinical application of fibrinogen concentrate in bleeding patients is included within a multimodal therapeutic concept and Logistic regression analysis showed positive correlation of postoperative plasma fibr inogen and survival.
Supplementation of fibrinogen in acquired bleeding disorders: experience, evidence, guidelines, and licences.
TLDR
Fibrinogen concentrate offers an attractive alternative to allogeneic blood products, as purification and viral inactivation during manufacture appear to minimize many of the risks associated with using blood products.
How I use fibrinogen replacement therapy in acquired bleeding.
TLDR
Point-of-care testing will have an important role in guiding fibrinogen replacement for hemostatic therapy in clinical settings such as cardiovascular surgery, postpartum hemorrhage, and trauma.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 19 REFERENCES
Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients
TLDR
Twelve out of 13 patients survived the first 24 h after treatment with relatively low doses of recombinant factor VIIa for large-scale bleeding, and Activation of factor X appeared to predict haemostatic efficacy.
Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy--a porcine model.
TLDR
During haemodilution, substitution of fibrinogen and PCC causes an enhancement of coagulation and final clot strength and this reversal of dilutional coagulopathy may reduce blood loss and mortality when large amounts of colloids are needed to maintain normovolaemia during huge blood losses.
Hemostatic Factors and Replacement of Major Blood Loss with Plasma-Poor Red Cell Concentrates
TLDR
It is concluded that deficiency of fibrinogen develops earlier than any other hemostatic abnormality when plasma-poor RCCs are used for the replacement of major blood loss.
[Fibrinogen substitution. Use in the treatment of bleeding due to lack of fibrinogen].
TLDR
Fibrinogen substitution may be done with fresh-frozen plasma, cryoprecipitate and virally inactivated concentrates of fibrinogene, which is critically important in haemostasis and may occur with a variety of underlying pathologies.
Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma.
TLDR
Early use of plasma and platelets at the upper end of recommended doses appears to reduce the incidence of coagulopathy in massively transfused individuals.
Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery.
TLDR
It is found that plasma FXIII activity does not influence postoperative bleeding in patients undergoing CPB surgery, and there is however an inverse association between preoperative or postoperative plasma fibrinogen levels and postoperative bleed.
Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate.
BACKGROUND Plasma substitutes such as hydroxyethyl starch (HES) and various dextrans may compromise the haemostatic system, thereby causing potentially dangerous bleeding. Whilst several mechanisms…
Fibrinogen Concentrate Reverses Dilutional Coagulopathy Induced In Vitro by Saline but Not by Hydroxyethyl Starch 6%
TLDR
Administration of fibrinogen after dilution with HES 6% failed to significantly improve clot firmness and platelets alone or in addition were not able to improve clot Firmness to a clinically relevant extent.
Practical guidelines for the clinical use of plasma.
Dextran and hydroxyethyl starch interfere with fibrinogen assays.
TLDR
The measured fibrinogen concentrations of patients receiving either dextran or hydroxyethyl starch (HES) were significantly higher than those predicted by the dilutional effects, which suggested that the presence of artificial colloids might interfere with the indirect fibr inogen assay used in the study.
...
1
2
...